Recursion Pharmaceuticals (RXRX) Non-Current Deffered Revenue (2020 - 2026)

Recursion Pharmaceuticals' Non-Current Deffered Revenue history runs 7 years deep, the most recent figure standing at $114.7 million for Q1 2026.

• Quarterly Non-Current Deffered Revenue fell 11.49% year-over-year to $114.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $114.7 million (down 11.49% YoY) and the FY2025 annual result came in at $114.0 million, down 4.0% from the prior year.
• Non-Current Deffered Revenue was $114.7 million for Q1 2026 at Recursion Pharmaceuticals, up from $114.0 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $129.6 million in Q1 2025 and bottomed at $15.7 million in Q3 2024.
• A 5-year average of $77.8 million and a median of $70.3 million in 2022 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue soared 3795.31% — and 2024, when it plunged 69.42%.
• Recursion Pharmaceuticals' Non-Current Deffered Revenue stood at $70.3 million in 2022, then decreased by 27.07% to $51.2 million in 2023, then surged by 131.79% to $118.8 million in 2024, then slipped by 4.0% to $114.0 million in 2025, then grew by 0.62% to $114.7 million in 2026.
• Business Quant data shows RXRX's Non-Current Deffered Revenue at $114.7 million in Q1 2026, $114.0 million in Q4 2025, and $111.2 million in Q3 2025.